티스토리 뷰
Leaf Therapeutics (LPTX) Investment Analysis: The correct name is “Leap Therapeutics” — positive ESMO 2025 data for the anti-DKK1 antibody sirexatamab (DKN-01) + company announced a name change to “Cypherpunk Technologies Inc.” on 2025-11-12 (ticker to sw
AI Prompt 2025. 11. 13. 00:09Leaf Therapeutics (LPTX) Investment Analysis: The correct name is “Leap Therapeutics” — positive ESMO 2025 data for the anti-DKK1 antibody sirexatamab (DKN-01) + company announced a name change to “Cypherpunk Technologies Inc.” on 2025-11-12 (ticker to switch to “CYPH” from 11/13)
※ Leap Therapeutics (NASDAQ: LPTX) is a biotech company developing the monoclonal antibody sirexatamab (DKN-01) that targets DKK1-expressing tumors. In October 2025, the company presented final ESMO 2025 results showing PFS/OS improvement in DKK1-high colorectal cancer, and on November 12, 2025 it announced a name change to “Cypherpunk Technologies Inc.” with the ticker to change to “CYPH” on November 13. 😅
📖 Company Introduction
(Watch the naming.) It’s not “Leaf” but Leap Therapeutics. The company has pursued clinical programs for sirexatamab (DKN-01, anti-DKK1) across gastro-esophageal, gynecologic, and colorectal cancers. On 2025-11-12, it announced a plan to change its name to “Cypherpunk Technologies Inc.” and adopt a digital-asset (ZEC) treasury strategy.
🧾 Company Overview
- Company/Ticker: Leap Therapeutics / LPTX → to trade as “Cypherpunk Technologies / CYPH” from 2025-11-13.
- Pipeline (high-level): sirexatamab (DKN-01, anti-DKK1), per company website/IR.
- Regulatory status: DKN-01 is not yet approved (in clinical development).
- Recent financing: Closed a private placement of approximately $58.88 million (2025).
- Recent clinical highlight: ESMO 2025 final data — significant PFS/OS improvement in DKK1-high CRC patients.
🏗️ Business Model (What They Do)
- (Past/core) Biotech R&D: biomarker-driven antibody therapeutics (centered on DKN-01).
- (Newly announced) Digital-asset treasury strategy: aims to accumulate Zcash (ZEC) and participate in its ecosystem—disclosed alongside the name/ticker change.
🚀 Bullish Factors
- Credibility from clinical data: At ESMO 2025, DKK1-high CRC showed PFS/OS benefit, supporting momentum for partnering and label expansion.
- Cash infusion events: ~$58.88M private financing strengthens the runway.
- Event-driven flows: Name/ticker change and strategy pivot can heighten headline sensitivity.
⚠️ Bearish Factors
- Microcap/headline volatility: Rebranding and a digital-asset strategy introduce non-traditional risks.
- Regulatory/clinical risk: DKN-01 remains unapproved—risk of delay/failure, cash burn, and further dilution.
- Strategic consistency concerns: A pivot from biotech to a digital-asset treasury can confuse the investment narrative.
💵 Financial / Trading Snapshot
- Ticker change: Trading as “CYPH” starting 2025-11-13—watch for symbol/data mismatches across platforms.
- Headline sensitivity: Shares may react strongly to rebranding, asset purchase/holdings disclosures, and clinical updates.
- Live quotes/charts: Always verify the current ticker and filings on your trading platform.
🔮 Checkpoints & Catalysts
- Post-switch disclosures (CYPH from 11/13): treasury details (e.g., ZEC holdings) and financial updates.
- DKN-01 follow-on clinical roadmap: confirmatory designs for DKK1-biomarker subgroups and partnering/licensing progress.
- Cash position/dilution path: use of proceeds from the private placement; any additional financing/ATM activity.
- Durability of the pivot: cadence and transparency of actual ZEC purchases/holdings, cost basis, and P&L impact.
📈 Technical Perspective (simple)
- Rules-based trading: Scaled entries/exits + ATR-based stops/targets to manage gap risk around news.
- Execution tactics: In high-volatility windows, prefer limit orders and staged fills to curb slippage.
- Event-driven posture: Size positions around ticker change, clinical readouts, treasury disclosures, and periodic filings.
💡 Investment Insights (Summary)
Leap (LPTX) is an atypical event play where a DKK1-targeted clinical story overlaps with rebranding and a strategy pivot. The key variables are how broadly the ESMO 2025 signal extends and the transparency/discipline of finance & governance after the pivot. Favor small sizing, event-centric tactics, and strict risk control.
❓ FAQs
Q1. Is it “Leaf Therapeutics”?
A. No. The correct name is “Leap Therapeutics.” As of 2025-11-12, the company announced a change to “Cypherpunk Technologies”.
Q2. Is DKN-01 an approved therapy?
A. No—still in clinical development.
Q3. What’s the latest clinical highlight?
A. ESMO 2025 final data showing PFS/OS improvement in DKK1-high CRC.
Q4. Biggest near-term catalysts?
A. Ticker transition (CYPH), DKN-01 trial designs/partnering, and ZEC treasury updates.